In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers

International Journal of Artificial Organs

Volumn 34, Issue 11, 2011, Pages 1067-1074

  Kumar, Atul ^a   Mann, Henry J ^b   Keshtgarpour, Mani ^c   Flynn, Michael A ^d   Deng, Hong ^e   Far, Adel Rafai ^e   Parr, Thomas R ^e   Moriarty, Susan R ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e Medicines Company   (Canada)

Author keywords

Clearance; CRRT; Hemodialysis; In vitro model; Oritavancin; Pharmacokinetics

Indexed keywords

BLOOD; HEMODIALYZERS; LIQUID CHROMATOGRAPHY;

CLEARANCE; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSATES; HAEMODIALYSIS; HIGH FLUX; HUMAN BLOODS; IN-VITRO MODELS; LOW FLUX; ORITAVANCIN; RENAL REPLACEMENT THERAPIES;

DIALYSIS;

ORITAVANCIN;

ARTICLE; ARTIFICIAL KIDNEY; BLOOD; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSATE; DRUG EFFICACY; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY BLOOD FLOW; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA CLEARANCE; STRUCTURE ACTIVITY RELATION;

EID: 84055207540     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000008     Document Type: Article

References (16)

1. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26(5):511-532.Medline. doi:10.1111/j.1574-6976.2003. tb00628.x
2. McKay GA, Fadhil I, Beaulieu S, et al. Oritavancin disrupts transmembrane potential and membrane integrity concom itantly with cell killing in Staphylococcus aureus and van comycin-resistant enterococci. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007. Washington, DC: American Society for Microbiology; 2007.
3. Weisbord SD, Palevsky PM. Acute renal failure in the intensive care unit. Semin Respir Crit Care Med. 2006;27(3):262-273. Medline. doi:10.1055/s-2006-945527
4. Golper TA, Marx MA, Shuler C, Bennett WM. Drug dosage in dialysis patients. In: Jacobs C, Kjellstand CM, Koch KM, Winchester J., eds. Replacement of renal function by dialysis. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996: 750-782.
5. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. Pediatr Nephrol. 2009;24(4):807-813. Medline. doi:10.1007/s00467-008-1083-8
6. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis. 2005;46(4):681-687. Medline. doi:10.1053/j.ajkd.2005.07.018
7. Hudson JQ, Comstock TJ, Feldman GM. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant. 2004;19(2):400-405. Medline. doi:10.1093/ndt/gfg550
8. Kielstein JT, Czock D, Schöpke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med. 2006;34(1):51-56. Medline. doi:10.1097/01. CCM.0000190243.88133.3F
9. Arhin FF, Belley A, McKay G, et al. Assessment of oritavancin serum protein binding across species. Antimicrob Agents Chemother. 2010;54(8):3481-3483. Medline. doi:10.1128/ AAC.00271-10
10. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53(10):4422-4428. Medline. doi:10.1128/AAC.00231-09
11. Eloot S, Torremans A, De Smet R, et al. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis. 2007;50(2):279-288. Medline. doi:10.1053/j.ajkd.2007.05.009
12. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother. 2005;49(5):1695-1700. Medline. doi:10.1128/AAC.49.5.1695-1700.2005
13. Domenech O, Francius G, Tulkens PM, Van Bambeke F, Dufrêne Y, Mingeot-Leclercq MP. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochim Biophys Acta. 2009;1788(9):1832-1840. Medline. doi:10.1016/j. bbamem.2009.05.003
14. Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008;52(5):1597-1603. Medline. doi:10.1128/AAC.01513-07
15. McMahon LP, Chester K, Walker RG. Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. Am J Kidney Dis. 2004;44(3):509-516.
16. Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrol Dial Transplant. 2002;17(9):1649-1654. Medline. doi:10.1093/ndt/17.9.1649.